

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/107, 47/02, 31/05		A1	(11) International Publication Number: WO 99/39696
			(43) International Publication Date: 12 August 1999 (12.08.99)
(21) International Application Number: PCT/US99/03036			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 10 February 1999 (10.02.99)			
(30) Priority Data: 09/021,671 10 February 1998 (10.02.98) US			
(71) Applicant: GENSLA SICOR INC. [US/US]; 19 Hughes, Irvine, CA 92718-1902 (US).			
(72) Inventors: MIREJOVSKY, Dorla; 19151 Sierra Maria, Irvine, CA 92612 (US). TANUDARMA, Liananingsih; 11502 Mossler Street, Anaheim, CA 92804 (US). ASHTEKAR, Dilip; 31 Woodwind, Irvine, CA 92614 (US).			
(74) Agents: WOLFF, Jessica, R. et al.; Lyon & Lyon LLP, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).			

Published


With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PROPOFOL COMPOSITION CONTAINING SULFITE

(57) Abstract

Sterile pharmaceutical compositions for parenteral administration containing 2, 6-diisopropylphenol (propofol) are described for use as anesthetics. The compositions comprise an oil-in-water emulsion of propofol additionally comprising an amount of sulfite sufficient to prevent significant growth of microorganisms for at least 24 h after adventitious contamination.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DESCRIPTIONPROPOFOL COMPOSITION CONTAINING SULFITE

5 This application is a continuation-in-part of application serial number 09/021,671, filed February 10, 1998 which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

10 In one aspect, the present invention relates to new pharmaceutical compositions containing 2,6-diisopropylphenol, known as propofol, and sulfite. In another aspect, the present invention relates to the use of these compositions to induce anesthesia in mammals, including sedation, and the induction and maintenance of
15 general anesthesia. In yet another aspect, the present invention relates to the use of sulfite as a preservative for parenterally administered oil-in-water emulsions, in general. In still another aspect, the
20 present invention relates to a process for the manufacture of oil-in-water emulsions containing sulfite as a preservative.

BACKGROUND OF THE INVENTION

25 2,6-Diisopropylphenol, generically named propofol, is a well-known and widely-used, injectable anesthetic with hypnotic properties used both as a sedative, and to induce and maintain general anesthesia. It is sold as Diprivan (trademark Zeneca) for human use and Rapinovel
30 (trademark Zeneca) for veterinary use. Propofol is administered directly into the bloodstream either by bolus injection or by infusion. Because the onset of

anesthesia is largely controlled by a drug's diffusion rate through the blood-brain barrier, propofol's lipophilicity is key to its rapid activity. This lipophilicity, however, renders propofol relatively insoluble in water, hence it must be administered in conjunction with solubilizing agents, surfactants, or solvents; or as oil-in-water emulsions (Jones et al. (1998) U.S. Patent 5,714,520). All references cited herein are incorporated by reference in their entirety.

10 As a parenterally administered agent, sterility of propofol formulations is essential. Commercial formulations are oil-in-water emulsions containing approximately 1% - 2% propofol in 10% soybean oil. These formulations also typically contain a surfactant, 1.2% egg phosphatide for example, 2.25% glycerol to make the formulation isotonic, sodium hydroxide to adjust the pH to physiological pH, and 0.005% EDTA equivalent (as edetate) to retard microbiological growth (all weights approximate) (*Id.*). Edetate containing formulations are not antimicrobially preserved by USP standards; however, 20 microbial growth is retarded (*Id.*).

Non-preserved, propofol oil-in-water emulsion formulations have significant drawbacks arising from the fact that these formulations support microbial growth: 25 strict aseptic handling technique is required; maximum utility time is 12 h maximum after vial entry. Handling recommendations include immediate administration after vial entry, and disposal of infusion assemblies and of unused material after 12 h. Nevertheless, reports of 30 nosocomial infections resulting from adventitious contamination are not uncommon (Bennett et al. (1995) *N. Engl. J. Med.* 333:147-154). Improper handling

techniques include delayed administration after transfer from vial to syringe, use of 50- and 100-mL products as multi-use, for multiple patients, and use of 50 and 100 mL products for an extended time period.

5 An application for which preserved propofol formulations are particularly advantageous is their use as a long-term sedative by continuous infusion. The risk of microbial contamination of non-preserved propofol in infusion devices increases both with
10 residency-time in the infusion device, and with increased manipulation of the device. The utility time of formulations containing EDTA salts (edetates) is at least 24 h compared to 6 to 12 h for non-preserved formulations (Jones et al.). A longer lasting
15 formulation means that fewer manipulations are required. The consequent reduced manipulation accrues a number of important benefits: reduced probability of microbial contamination, reduced probability of operator error, reduced drug waste, and reduced labor intensiveness -
20 all of which combine to increase safety and reduce costs.

SUMMARY OF THE INVENTION

25 An extensive and vigorous evaluation of known antimicrobial agents for parenteral products led to the unexpected discovery that sulfite can be included in an oil-in-water emulsion of propofol in a non-toxic amount which is soluble in the aqueous phase and does not partition into the organic phase, and which retards or
30 suppresses the of growth of likely microbial contaminants, without destabilizing the emulsion and without adversely reacting with other formulation

components. These results are especially surprising in light of published data indicating that sodium metabisulfite is completely ineffectual for this particular application (1% Diprivan (Zeneca) 0.1%

5 $\text{Na}_2\text{S}_2\text{O}_5$) (Jones et al.).

Sodium metabisulfite is a salt of a sulfurous acid (formally, metasulfurous acid). The present invention includes all pharmaceutically acceptable derivatives of sulfurous acid (orthosulfurous acid) and metasulfurous
10 acid approved by the FDA for human use (sulfites) and any combinations thereof. These compounds include, but are not limited to, sodium sulfite, sodium bisulfite, potassium sulfite, potassium bisulfite, sodium metabisulfite, and potassium metabisulfite.

15 Accordingly, the present invention provides a sterile composition for parenteral administration comprising an oil-in-water emulsion in which propofol is dissolved in a water-immiscible solvent that is emulsified with water wherein said emulsion is
20 stabilized by means of a surfactant. The composition further comprises an amount of a sulfite sufficient to exhibit antimicrobial activity against microorganisms most likely to contaminate the propofol preparation.

The present invention also includes the use of
25 sulfites as preservatives for any sterile, parenterally administered oil-in-water emulsion. In addition to propofol compositions, such formulations include total-parenteral-nutrition formulations, or oil-in-water vehicles for other pharmaceutical or therapeutic agents.

30 Additionally, the present invention includes a process for the manufacture of sterile, propofol oil-in-water emulsions for parenteral administration comprising

propofol dissolved into a water-immiscible liquid emulsified with water, wherein said emulsion is stabilized by means of a surfactant and further comprising effective amounts of sulfite as a
5 preservative. Timing of the addition of the sulfite and control of the process temperature are both critical to the maintenance of antimicrobial activity in the composition. This aspect of the invention may be advantageously applied to other drugs formulated as an
10 oil-in water emulsion.

DEFINITIONS

In accordance with the present invention and as used herein, the following terms are defined to have the
15 following meanings, unless explicitly stated otherwise:

The term "edetate" refers to an anion derived from deprotonation of EDTA. EDTA is a tetrabasic acid, thus an edetate may be mono-, di-, tri- or tetraanionic. The term "edetate" may also refer to a salt of an edetate
20 anion.

The term "oil-in-water emulsion" refers to a distinct two phase system that is in equilibrium and in effect, as a whole, is kinetically stable and thermodynamically unstable.

25 The term "preservative" refers to an agent or agents that suppress or prevent microbiological growth at 24 h by no more than 10-fold compared to time-zero.

The term "sulfite" refers to all pharmaceutically acceptable derivatives of sulfurous acid (orthosulfurous
30 acid) and metasulfurous acid approved by the FDA now or in the future for human use. These compounds include sodium sulfite, sodium bisulfite, potassium sulfite,

potassium bisulfite, sodium metabisulfite, and potassium metabisulfite.

BRIEF DESCRIPTION OF THE DRAWINGS

- 5 **Figure 1.** Flow chart for the manufacturing process for sterile propofol oil-in-water emulsion formulations containing sodium metabisulfite.

DETAILED DESCRIPTION OF THE INVENTION

- 10 Development of a preservative-containing, oil-in-water emulsion formulations is a daunting task. Key requirements for the preservative include:
- a. Soluble in the aqueous phase, does not partition into the organic phase;
 - 15 b. Low toxicity, since large volumes are commonly used;
 - c. Retardation/suppression of growth of likely microbial contaminants;
 - d. Compatibility with all other formulation components;
 - 20 e. Not destabilizing of the emulsion.

Many currently used preservatives are lipophilic, and hence, would be ineffective for use in oil-in-water emulsions because of requirement a. Emulsion physical stability and clinical performance depend critically on the particle-size distribution and the number of large particles (requirement e) (Dabbah et al. (1995) in *USP Open Conference-Microbiological Compendial Issues The*

25 United States Pharmacopeial Convention, pp 87-96).

Sodium metabisulfite, sodium bisulfite, sodium sulfite, potassium metabisulfite, and potassium sulfite

are used in many parenteral formulations as antioxidants and/or antimicrobials in concentrations of 0.025 - 0.66%. The antimicrobial activity, however, requires a pH in the 2.5 - 5.5 range. Oil-in-water emulsions, on the other hand, are typically formulated at pH 6 - 9 to assure the ionization of the headgroups of the phospholipid surfactants incorporated therein. The resulting electrostatic repulsion favors the formation of small oil particles and discourages their coalescence with time. We have discovered stable emulsions containing each of the above sulfite-containing compounds in the 4.5 - 6.4 pH range that nevertheless exhibit antimicrobial activity. We have also discovered a process for the manufacture of these emulsions which minimizes the loss of the sulfite-containing compounds through autooxidation.

While not wishing to be limited to this mechanism, the inventors believe that the inhibition and destruction of microorganisms by sodium metabisulfite, sodium bisulfite, sodium sulfite, potassium metabisulfite, and potassium sulfite is highest at lower pH values. The primary activity of these compounds is believed to be due to the formation of sulfurous acid (H_2SO_3) and bisulfite ions. The antimicrobial action is believed to be due to inhibition of enzyme systems, especially through oxidation of SH groups in enzymes and proteins. The bisulfite ions may also interact with pyrimidine bases (Foegeding, P.M. and Busta, F.F. "Chemical Food Preservatives," pp 802-832, in Disinfection, Sterilization, and Preservation, fourth edition, Ed S.S. Block, 1991, Pub. Lea and Febiger, William and Wilkins, Philadelphia, USA).

1. Pharmaceutical Compositions

The composition of the present invention comprises a sulfite, preferably a salt of metasulfurous acid.

5 More preferably, the sulfite is sodium metabisulfite and other sulfurous acid salts such as sodium bisulfite, sodium sulfite, potassium metabisulfite, or potassium sulfite. The sulfite will typically be present from about 0.0075% to about 0.66% weight. Preferably, the
10 sulfite is present in the range of about 0.0075% to about 0.1% weight and most preferably about 0.025% weight. It will be apparent to one skilled in the pharmaceutical arts that other sulfites may be used in these compositions and that their weight percentages
15 will depend on the particular sulfite used.

Maximal dosages of sulfite will occur in long-term infusion situations, for example when used as a sedative. Typical dosages of propofol are 0.3 - 3 mg/kg/h, but may range to 10 mg/kg/h in exceptional
20 cases, equivalent to 1.68 L emulsion/day/70 kg. Under these conditions, the total sulfite administered is well below the limit set by the World Health Organization (WHO) (7.0 mg/kg as SO₂) and is below the amount infused in total-parenteral-nutrition amino acid formulations,
25 as well as during peritoneal dialysis (Gunnison and Jacobsen (1987) *Crit. Rev. Toxicol.* 17:185-214).

The composition of the present invention typically comprises 0.1 to 5% weight propofol. Preferable compositions comprise from about 1% to about 2% weight
30 propofol. More preferable compositions are about 1% weight and about 2% weight propofol. The propofol may be dissolved in a pharmaceutically acceptable water-

immiscible solvent and emulsified in water and said emulsion stabilized by means of a surfactant; or the propofol may itself be emulsified in water without addition of a water-immiscible solvent and said emulsion
5 stabilized by means of a surfactant.

Water-immiscible solvents suitable for the preparation of oil-in-water emulsions suitable for parenteral administration are known to those skilled in the pharmaceutical arts (*Handbook of Pharmaceutical*
10 *Exipients* Wade and Weller, Eds. (1994) American Pharmaceutical Association, The Pharmaceutical Press: London, pp 451-453). Typically, the water-immiscible solvent will be a vegetable oil: for example, soybean, safflower, cottonseed, corn, sunflower, arachis, and
15 castor. The water-immiscible solvent may also be a wholly or partially manufactured material, for example mono-, di-, and triglycerides, fatty acid esters, or chemically and/or physically modified vegetable oils. The present invention may also comprise any combination
20 of said water-immiscible solvents. When used, the water-insoluble solvent comprises up to about 30% weight of the composition, preferably in the range of about 5% to about 25% weight, more preferably in the range of about 10% to about 20% weight, most preferably about 10%
25 weight.

The composition of the present invention comprises a pharmaceutically acceptable surfactant which aids in the emulsification of the water-immiscible phase in water and stabilizes said emulsion (*Id.*). Suitable
30 surfactants include naturally occurring surfactants: for example, egg or soy phosphatides, either in their native or modified forms; manufactured non-ionic surfactants,

for example a polyethylene glycol or esters thereof; or any mixture thereof. Preferable surfactants are egg or soy phosphatides, for example egg-yolk phospholipid. The amount of surfactant effective in producing and
5 maintaining a stable oil-in-water emulsion will depend the particular formulation. The factors and their relationships are well known to skilled practitioners in the pharmaceutical arts. These factors include the presence or absence of a water-immiscible solvent, the
10 particular water-immiscible solvent used, the particular surfactant employed, the presence of salts, and the pH of the composition.

Preferably, the total number of fat globules/0.1 mL in the 1-20 μm particle size range is $\leq 600,000$ and in
15 the 5-20 μm particle size range is $\leq 200,000$. Preferably, the % volume of total fat globules/0.1 mL in the 1-20 μm particle size range is ≤ 0.3 and is ≤ 0.2 in the 5-20 μm size range. Preferably, the mean fat globule size is less than 500nm, and more preferably
20 less than 250nm.

The composition of the present invention is formulated with pH in the range of about 4.5 to about 6.4. The pH may be adjusted as required by means of addition of an alkali, for example sodium hydroxide, or
25 an acid, for example hydrochloric acid.

The composition of the present invention may be made isotonic with blood by incorporation of a suitable tonicity modifier, for example glycerin (*Id.*).

The compositions of the present invention are
30 sterile, aqueous formulations and are prepared by standard manufacturing techniques using, for example, aseptic manufacturing methods and sterilization by

autoclaving.

Compositions of the current invention may be formulated to match commercial formulations in clinical performance and physical properties. Tables 1 below
5 compares the composition of the preferred embodiment of the present invention with Diprivan. Table 2 below compares the physical properties of these two formulations.

Table 1. Comparison the formulation of a composition of the present invention with a commercial formulation.

Component	Propofol Injectable Emulsion 1%	DIPRIVAN Injectable Emulsion 1%
Propofol, mg/mL	10	10
Soybean oil, mg/mL	100	100
Glycerin, mg/mL	22.5	22.5
Egg-yolk phospholipid, mg/mL	12	12
Disodium edetate, mg/mL	-	0.05
Sodium metabisulfite, mg/mL	0.25	-
WFI q.s. to 1 mL		
pH	4.5 - 6.4	7.0 - 8.5

Diprivan trademark of Zeneca..

Table 2. Comparison of physical properties of a composition of the present invention with a commercial formulation.

Physico-Chemical Parameter	Propofol Injectable Emulsion 1%	DIPRIVAN Injectable Emulsion 1%
Appearance	White emulsion with no visible oil droplets	White emulsion with no visible oil droplets
Density	0.995	0.995
Osmolality, mg/mL	300	300
Viscosity, centistokes	1.6	1.6 - 1.7

Diprivan trademark of Zeneca.

The following Table 3 shows that the particle size distribution of the emulsion containing sodium metabisulfite, sodium bisulfite, sodium sulfite, potassium metabisulfite, or potassium sulfite are comparable to the Zeneca product containing 0.005% EDTA. The data show that the addition of any of the salts did not cause an increase in the number of large particles which is a concern for injectable emulsions.

The size of particles with a submicron diameter (<1 μ m) is monitored using Nicomp 370, manufactured by Particle Sizing Systems, Santa Barbara, CA. This instrument measures an apparent average particle size and distribution. The size and the number of fat globules larger than 1 μ m are determined using the AccuSizer™ 770 manufactured by Particle Sizing Systems, Santa Barbara, California. This technique allows separate monitoring of the number of particles and % volume of the oil taken by these particles for the 1-20 μ m and 5-20 μ m diameter ranges.

Table 3

	Total Number of Fat Globules/0.1 mL		% Volume of Total Fat Globules/0.1 mL		Mean Fat Globule Size nm
	Particle Size 1-20µm	Particle Size 5-20 µm	Particle Size 1-20 µm	Particle Size 5-20 µm	
Diprivan Injectable Emulsion 1% (Average of 3 different lots)	312,911 ± 117,479	17,095 ± 6,398	0.050 ± 0.019	0.025 ± 0.010	194 ± 6
Propofol Injectable Emulsion 0.025% Sodium Metabisulfite (Average of 2 different lots)	311,894 ± 71,940	3,122 ± 642	0.022 ± 0.005	0.009 ± 0.002	198 ± 2
Propofol Injectable Emulsion (0.025%) of:					
Sodium Bisulfite	100,691	3,347	0.012	0.004	201
Sodium Sulfite	128,338	6,689	0.021	0.010	239
Potassium Metabisulfite	156,569	6,470	0.022	0.011	197
Potassium Sulfite	50,151	1,716	0.006	0.005	202

The compositions of the present invention are useful as anesthetics including sedation, and induction and maintenance of general anesthesia. Thus, in another aspect, the present invention provides a method for inducing anesthesia in mammals which comprises parenteral administration of a sterile, aqueous pharmaceutical composition comprising an oil-in-water

SD-101809.1

emulsion in which propofol, either alone or dissolved in a water-immiscible solvent, is emulsified in water, wherein said emulsion is stabilized by means of a surfactant; which further comprises an effective amount
5 of sulfite.

Dosage levels appropriate for the induction of desired degree of anesthesia, for example sedation, or induction of or maintenance of general anesthesia, by the compositions of the present invention will depend on
10 the type of mammal under treatment and the physical characteristics of the specific mammal under consideration. These factors and their relationship in determining this amount are well known to skilled practitioners in the medical arts. Approximate dosage
15 levels may be derived from the substantial literature on propofol, may be tailored to achieve optimal efficiency, and will be contingent on myriad factors recognized by those skilled in the medical arts including weight, diet, and concurrent medication.

20 The antimicrobial effects of sulfites may also be advantageously applied to other sterile, oil-in-water emulsions for parenteral administration. Examples include total-parenteral-nutrition formulations and oil-in-water emulsions of other pharmaceuticals or
25 therapeutic agents.

Oil-in-water emulsion total-parenteral-nutrition formulations are administered by infusion to patients for whom oral nutrition is impossible, undesirable, or insufficient. The emulsified lipids provide a
30 concentrated caloric content. These formulations may also contain other nutrients, for example amino acids, vitamins, and minerals. Commercial examples of such

formulations include Intralipid (trademark Pharmacia), Lipofundin (trademark Braun), and Travamulsion (trademark Baxter). Accordingly, the present invention provides a sterile total-parenteral-nutrition
5 formulation comprising lipids or fats emulsified in water which further comprises an effective amount of sulfite as a preservative.

A wide variety of current and potential pharmaceutical or therapeutic agents are highly
10 lipophilic, for example steroids, prostaglandins, leukotrienes, and fat-soluble vitamins. Such compounds may be advantageously administered in oil-in-water emulsion vehicles comprising a sulfite as a preservative, particularly when administration will
15 occur over an extended period. Accordingly, the present invention provides a sterile, therapeutic composition comprising a lipophilic pharmaceutical or therapeutic agent, either alone or dissolved in a water-immiscible solvent, emulsified in water, which further comprises an
20 amount of sulfite effective as a preservative.

2. Process for Manufacture

A scheme for the manufacture of compositions of the
25 present invention is shown in Figure 1. The present invention provides a process for manufacturing the compositions of the present invention comprising the steps of:

1. Preparing an aqueous phase by adding glycerin
30 and sodium hydroxide into about 80% WFI in a compounding tank while maintaining the temperature at approximately 40 °C;

2. Adding the egg-yolk phospholipid to said aqueous phase;
3. Homogenizing said aqueous phase;
4. Filtering said aqueous phase through a 5.0 μm filter;
- 5 5. Preparing an oil phase by dissolving propofol in soybean oil;
6. Filtering said oil phase through a 0.45 μm filter;
- 10 7. Combining and homogenizing said aqueous and oil phases;
8. Adding a solution of a sulfite compound dissolved in WFI near the end of the homogenization step;
- 15 9. Adding sodium hydroxide or hydrochloric acid solution to adjust the pH;
10. Adjusting to specified volume with WFI;
11. Microfluidizing the crude emulsion to the target globule size and particle size
- 20 distribution while maintaining the temperature at about 30 °C;
12. Filtering the propofol oil-in-water emulsion into a filling vessel;
13. Filling and sealing containers under nitrogen;
- 25 14. Autoclaving said containers.

Typically, 12 mg/L of sodium hydroxide is added in step 3. Preferably, all steps are performed under a nitrogen atmosphere.

- Timing of the addition of the sulfite is critical.
- 30 If dissolved in the aqueous phase in step 3 or 4, the antimicrobial activity is lost, presumably from loss of bisulfite during processing. Optimal antimicrobial

activity was obtained when the sulfite was added at step 10. Typically, the sulfite is added by a stock solution of about 54 g/L after 25 minutes of homogenization. Typically, the mixture is homogenized for an additional 5 minutes. Furthermore, the thermal lability and sensitivity to oxidation of the sulfites necessitate accurate temperature control and a nitrogen or other inert gas environment in the manufacturing process.

This procedure may be modified to prepare other compositions of the present invention by substituting other water immiscible solvents for the soybean oil, other surfactants for the egg yolk phospholipid, other acids or bases to adjust the pH instead of sodium hydroxide, and/or other tonicity modifiers for the glycerin. The procedure may also be modified to prepare other drugs in a preserved oil-in-water emulsion or those for parenteral nutrition.

3. Microbiological Activity

The growth retarding capability of 1% propofol injectable emulsion containing sodium metabisulfite, sodium bisulfite, sodium sulfite, potassium metabisulfite, or potassium sulfite were evaluated using membrane filtration technique and broth cultures. Approximately 50 - 200 colony forming units (CFU) per mL of four standard organisms recommended by United States Pharmacopeia (USP) for preservative efficacy tests were inoculated in each formulation. These four organisms are identified as *Staphylococcus aureus* (ATCC 6538), *Escherichia coli* (ATCC 8739), *Pseudomonas aeruginosa* (ATCC 9027), and *Candida albicans* (ATCC 10231). In addition to these organisms, *S. epidermidis* (ATCC 12228)

and *S. aureus* (coagulase negative, ATCC 27734) were also tested.

The antimicrobial activity of propofol containing sodium metabisulfite was compared with propofol containing 0.005% disodium ethylenediaminetetraacetic acid (Diprivan EDTA, trademark Zeneca), and a control propofol formulation lacking preservative. After the inoculation of the test organisms, test formulations were incubated at 30 - 35 °C. The viable count of the test organism was determined immediately following the inoculation and after 24 h of incubation at 30 - 35 °C. Each datum for the metabisulfite composition is the average of eight determinations performed on two fresh 20-mL vials, two 1-month stability 20-mL vials, two fresh 100-mL vials, and two 1-month stability 100-mL vials. The Diprivan samples were from four fresh 50-mL vials. Unpreserved propofol samples contained the same ingredients, except they contained no preservatives. The preservative was considered effective if the microbial growth was suppressed, or allowed for a no-more-than 10-fold increase in growth as compared to the zero-hour viable count (count of the organism immediately following inoculation) of each of the test organisms.

The following Tables 4-12 compare the antimicrobial effectiveness of sodium metabisulfite and other sulfite formulations with that of Diprivan and unpreserved propofol. These results indicate that sodium metabisulfite and the other sulfite compounds are

competent to prevent the significant growth of microorganisms for at least 24 h after adventitious, extrinsic contamination.

Table 4. Comparison of microbial growth retarding activity of various formulations against *S. aureus* (ATCC 6538).

Formulation (number of samples)	Viable count of survivors \log_{10} CFU/mL \pm SD		Decrease in survivors
	0 h	24 h	\log_{10} CFU/mL
Propofol metabisulfite (8)	2.08 \pm 0.28	ND	2.08
Diprivan EDTA (4)	2.37 \pm 0.26	1.55 \pm 0.58	0.82
Unpreserved Propofol (2)	2.0	5.5	NA

5 NA: Not applicable. ND: No viable organisms detected in
1-mL aliquot. SD: standard deviation.

Table 5. Comparison of microbial growth retarding activity of various formulations against *S. epidermidis* (ATCC 12228).

Formulation (number of samples)	Viable count of survivors \log_{10} CFU/mL \pm SD		Decrease in survivors
	0 h	24 h	\log_{10} CFU/mL
Propofol metabisulfite (8)	2.27 \pm 0.04	ND	2.27
Diprivan EDTA (4)	2.20 \pm 0.34	1.05 \pm 0.35	1.15
Unpreserved Propofol	2.4	4.55 \pm 0.07	NA

NA: Not applicable. ND: No viable organisms detected in
5 1-mL aliquot. SD: standard deviation.

Table 6. Comparison of microbial growth retarding activity against *E. coli* (ATCC 8739) of various formulations.

Formulation (number of samples)	Viable count of survivors \log_{10} CFU/mL \pm SD		Decrease in survivors
	0 h	24 h	\log_{10} CFU/mL
Propofol metabisulfite (8)	2.26 \pm 0.05	2.28 \pm 0.13	NA
Diprivan EDTA (4)	2.37 \pm 0.09	0.275 \pm 0.55	2.095
Unpreserved Propofol	2.3	7.25 \pm 0.07	NA

NA: Not applicable. ND: No viable organisms detected in
5 1-mL aliquot. SD: standard deviation.

Table 7. Comparison of microbial growth retarding activity of various formulations against *P. aeruginosa* (ATCC 8739).

Formulation (number of samples)	Viable count of survivors \log_{10} CFU/mL \pm SD		Decrease in survivors
	0 h	24 h	\log_{10} CFU/mL
Propofol metabisulfite (8)	1.97 \pm 0.26	ND	1.97
Diprivan EDTA (4)	1.97 \pm 0.17	2.50 \pm 0.47	NA
Unpreserved Propofol	2.35 \pm 0.07	6.8	NA

5 NA: Not applicable. ND: No viable organisms detected in 1-mL aliquot. SD: standard deviation.

Table 8. Comparison of microbial growth retarding activity against *S. aureus* (coagulase negative, ATCC 27734) of various formulations.

Formulation (number of samples)	Viable count of survivors \log_{10} CFU/mL \pm SD		Decrease in survivors
	0 h	24 h	\log_{10} CFU/mL
Propofol metabisulfite (8)	2.28 \pm 0.22	ND	2.28
Diprivan EDTA (4)	2.87 \pm 0.05	2.07 \pm 0.28	0.80
Unpreserved Propofol	3.15 \pm 0.07	7.05 \pm 0.07	NA

5 NA: Not applicable. ND: No viable organisms detected in
1-mL aliquot. SD: standard deviation.

Table 9. Comparison of microbial growth retarding activity against *C. albicans* (ATCC 10231) of various formulations.

Formulation (number of samples)	Viable count of survivors \log_{10} CFU/mL \pm SD		Decrease in survivors
	0 h	24 h	\log_{10} CFU/mL
Propofol metabisulfite (8)	2.42 \pm 0.08	3.13 \pm 0.22	NA
Diprivan EDTA (4)	2.30 \pm 0.08	3.20 \pm 0.28	NA
Unpreserved Propofol	2.3	5.10 \pm 0.14	NA

5 NA: Not applicable. ND: No viable organisms detected in 1-mL aliquot. SD: standard deviation.

Table 10. Comparison of microbial growth retarding activity against *E. coli* (ATCC 8739) of various sulfite-containing propofol injectable emulsion formulations (0.025%).

Formulations	Viable count of survivors \log_{10} CFU/mL \pm SD		Decrease in survivors \log_{10} CFU/mL
	<u>0 h</u>	<u>24 h</u>	
Propofol injectable emulsion with:			
Sodium bisulfite	2.3	1.7	0.6
	2.3	2.2	0.1
Sodium sulfite	2.3	1.3	1.0
	2.3	1.4	0.9
Potassium metabisulfite	2.3	2.0	0.3
	2.3	2.0	0.3
Potassium sulfite ¹	2.3	4.8	NA
	2.3	4.7	NA
Diprivan (50 ml)	2.5	0.5	2.0
	2.5	0.3	2.2
Propofol without antimicrobial agent	2.3	7.3	NA

5 NA: Not applicable. ND: No viable organisms detected in 1-mL aliquot. SD: standard deviation.

¹ Formulation contained 0.03 mg/mL or 0.003% potassium sulfite. The inventors believe that a higher level of potassium sulfite will improve the inhibition of microbial growth.

SD-101809.1

Table 11. Comparison of microbial growth retarding activity against *C. albicans* (ATCC 10231) of various sulfite-containing propofol injectable emulsion formulations (0.025%).

Formulations	Viable count of survivors \log_{10} CFU/mL \pm SD		Decrease in survivors \log_{10} CFU/mL
	<u>0 h</u>	<u>24 h</u>	
Propofol injectable emulsion with:			
Sodium bisulfite	2.3	1.6	0.7
	2.3	1.4	0.9
Sodium sulfite	2.3	ND	2.3
	2.3	ND	2.3
Potassium metabisulfite	2.2	1.8	0.4
	2.3	2.0	0.3
Potassium sulfite ²	2.5	4.5	NA
	2.4	4.5	NA
Diprivan (50 mL)	2.5	3.4	NA
	2.5	3.4	NA
Propofol without antimicrobial agent	2.3	5.1	NA

5 NA: Not applicable. ND: No viable organisms detected in 1-mL aliquot. SD: standard deviation.

² Formulation contained 0.03 mg/mL or 0.003% potassium sulfite. The inventors believe that a higher level of potassium sulfite will improve the inhibition of microbial growth.

SD-101809.1

5 **Table 12.** Comparison of microbial growth retarding activity against *P. aeruginosa* (ATCC 9027) of various sulfite-containing propofol injectable emulsion formulations (0.025%).

Formulations	Viable count of survivors \log_{10} CFU/mL \pm SD		Decrease in survivors \log_{10} CFU/mL
	<u>0 h</u>	<u>24 h</u>	
Propofol injectable emulsion with:			
Sodium bisulfite	1.8	ND	1.8
	1.8	ND	1.8
Sodium sulfite	1.5	ND	1.5
	1.4	ND	1.4
Potassium metabisulfite	2.4	ND	2.4
	2.4	ND	2.4
Potassium sulfite ³	2.3	ND	2.3
	2.3	ND	2.3
Diprivan (50 mL)	2.5	3.4	NA
	2.4	3.3	NA
Propofol without antimicrobial agent	2.4	6.8	NA

NA: Not applicable. ND: No viable organisms detected in 1-mL aliquot. SD: standard deviation.

³ Formulation contained 0.03 mg/mL or 0.003% potassium sulfite. In spite of this low concentration, the potassium sulfite was still effective in inhibiting growth of *P. aeruginosa*.
SD-101809.1

The present invention provides a sterile pharmaceutical preparation of propofol that comprises an amount of sulfite sufficient to significantly prevent the growth, or prevent no more than 10-fold increase in growth of each of *S. aureus* (ATCC 6538), *E. coli* (ATCC 8739), *P. aeruginosa* (ATCC 9027), and *C. albicans* (ATCC 10231) *S. epidermidis* (ATCC 12228) and *S. aureus* (coagulase negative, ATCC 27734). Preferably, the sulfite is sodium metabisulfite, sodium bisulfite, sodium sulfite, potassium metabisulfite, or potassium sulfite. Furthermore, in the event of improper aseptic handling of the finished product leading to an accidental extrinsic contamination, the present formulation will suppress, minimize, or limit the chance of microbial growth for at least 24 h.

EXAMPLES

Preferred compositions are as follows:

1% propofol emulsion for injection:

- a. about 1% propofol;
- 5 b. about 10% weight soybean oil;
- c. about 2.25% weight glycerin;
- d. about 1.2% weight egg-yolk phospholipid;
- e. about 0.025% weight sulfite;
- f. sodium hydroxide;
- 10 g. water to 100%.

2% propofol emulsion for injection:

- a. about 2% propofol;
- b. about 10% weight soybean oil;
- 15 c. about 2.25% weight glycerin;
- d. about 1.2% weight egg-yolk phospholipid;
- e. about 0.025% weight sulfite;
- f. sodium hydroxide;
- g. water to 100%.

20 Preferably, these formulations have pH of approximately 4.5-6.4.

The above examples of compositions, and methods of manufacturing same are exemplary and the invention is not limited solely to those examples.

We claim:

1. A sterile, pharmaceutical composition for parenteral administration which comprises an oil-in-water emulsion in which propofol is dissolved in a water-immiscible solvent, is emulsified with water, and is stabilized by means of a surfactant, and which further comprises an amount of sulfite sufficient to prevent a no more than 10-fold increase in the growth of each of *Staphylococcus aureus* (ATCC 6538), *Escherichia coli* (ATCC 8739), *Pseudomonas aeruginosa* (ATCC 9027), and *Candida albicans* (ATCC 10231) for at least 24 h as measured by a test wherein a washed suspension of each organism is added to a separate aliquot of said composition at approximately 50 colony-forming units per mL and incubated at a temperature in the range 30 - 35 °C and are tested for viable counts of said organisms after 24 h.

2. The sterile, pharmaceutical composition according to claim 1 wherein the sulfite is selected from the group consisting of sodium metabisulfite, sodium sulfite, sodium bisulfite, potassium metabisulfite, and potassium sulfite.

25

3. The sterile, pharmaceutical composition according to claim 2 wherein said sulfite is sodium metabisulfite.

4. The sterile, pharmaceutical composition according to claim 1 which comprises up to about 30% weight of a water-immiscible solvent.

5 5. The sterile, pharmaceutical composition according to claim 4 which comprises from about 10% to about 20% weight of a water-immiscible solvent.

6. The sterile, pharmaceutical composition
10 according to claim 1 wherein the water-immiscible solvent is a vegetable oil or ester of a fatty acid.

7. The sterile, pharmaceutical composition according to claim 6 wherein the vegetable oil is
15 soybean oil.

8. The sterile, pharmaceutical composition according to claim 1 wherein the surfactant is a naturally occurring phosphatide.
20

9. The sterile, pharmaceutical composition according to claim 8 wherein the phosphatide is egg phosphatide or soy phosphatide.

25 10. The sterile, pharmaceutical composition according to claim 1 wherein the pH is between about 4.5 to about 6.4.

11. The sterile, pharmaceutical composition
30 according to claim 10 wherein sodium hydroxide is present.

12. The sterile, pharmaceutical composition according to claim 1 which is isotonic with blood.

13. The sterile, pharmaceutical composition
5 according to claim 12 which is made isotonic with blood by incorporation of glycerin.

14. The sterile, pharmaceutical composition according to claim 1 which comprises from about 1% to
10 about 2% weight propofol.

15. The sterile, pharmaceutical composition according to claim 14 which comprises about 1% weight propofol.

15

16. The sterile, pharmaceutical composition according to claim 14 which comprises about 2% weight propofol.

20 17. A sterile, pharmaceutical composition for parenteral administration which comprises an oil-in-water emulsion in which propofol is dissolved in a water-immiscible solvent, is emulsified with water, and is stabilized by means of a surfactant, and which
25 further comprises an amount of sulfite wherein the amount of sulfite is in the range of about 0.0075% to about 0.66% weight.

18. The sterile, pharmaceutical composition according to claim 17 wherein the amount of sulfite is in the range of about 0.0075% to about 0.1% weight.

5 19. The sterile, pharmaceutical composition according to claim 18 wherein the amount of sulfite is about 0.025% weight.

10 20. The sterile, pharmaceutical composition according to claims 17, 18 or 19 which comprises up to 30% weight of a water-immiscible solvent.

15 21. The sterile, pharmaceutical composition according to claim 20 which comprises from about 10% to about 20% weight of a water-immiscible solvent.

20 22. The sterile, pharmaceutical composition according to claims 17, 18 or 19 wherein the water-immiscible solvent is a vegetable oil or ester of a fatty acid.

25 23. The sterile, pharmaceutical composition according to claim 22 wherein the vegetable oil is soybean oil.

24. The sterile, pharmaceutical composition according to claims 17, 18 or 19 wherein the surfactant is a naturally occurring phosphatide.

25. The sterile, pharmaceutical composition according to claim 24 wherein the phosphatide is egg phosphatide or soy phosphatide.

5 26. The sterile, pharmaceutical composition according to claims 17, 18 or 19 wherein the pH is between about 4.5 to about 6.4.

10 27. The sterile, pharmaceutical composition according to claim 26 wherein sodium hydroxide is present.

15 28. The sterile, pharmaceutical composition according to claims 17, 18 or 19 which is isotonic with blood.

20 29. The sterile, pharmaceutical composition according to claim 28 which is made isotonic with blood by incorporation of glycerin.

30. The sterile, pharmaceutical composition according to claims 17, 18 or 19 which comprises from about 1% to about 2% weight propofol.

25 31. The sterile, pharmaceutical composition according to claim 30 which comprises about 1% weight propofol.

32. The sterile, pharmaceutical composition according to claim 30 which comprises about 2% weight propofol.

5 33. The sterile, pharmaceutical composition of claim 17 wherein the sulfite is selected from the group consisting of sodium metabisulfite, sodium sulfite, sodium bisulfite, potassium metabisulfite, and potassium sulfite.

10 34. The pharmaceutical composition of claim 33 wherein said sulfite is sodium metabisulfite.

15 35. A sterile, pharmaceutical composition for parenteral administration which comprises by weight:

- a. about 1% propofol;
- b. about 10% soybean oil;
- c. about 2.25% glycerin;
- d. about 1.2% egg-yolk phospholipid;
- 20 e. about 0.025% of any of sodium metabisulfite, sodium bisulfite, sodium sulfite, potassium metabisulfite, or potassium sulfite, or any combination thereof;
- 25 f. sodium hydroxide; and
- g. water to 100%.

30 36. A sterile, pharmaceutical composition for parenteral administration which comprises by weight:

- a. about 2% propofol;
- b. about 10% soybean oil;
- c. about 2.25% glycerin;

- d. about 1.2% egg-yolk phospholipid;
- e. about 0.025% of any of sodium metabisulfite, sodium bisulfite, sodium sulfite, potassium metabisulfite, or potassium sulfite, or any combination thereof;
- f. sodium hydroxide; and
- g. water to 100%.

10 37. A sterile, pharmaceutical composition for parenteral administration which comprises an oil-in-water emulsion in which propofol is emulsified with water, and is stabilized by means of a surfactant, and which further comprises an amount of sulfite sufficient
15 to prevent a no more than 10-fold increase in the growth of each of *Staphylococcus aureus* (ATCC 6538), *Escherichia coli* (ATCC 8739), *Pseudomonas aeruginosa* (ATCC 9027), and *Candida albicans* (ATCC 10231) for at least 24 h as measured by a test wherein a washed
20 suspension of each organism is added to a separate aliquot of said composition at approximately 50 colony-forming units per mL and incubated at a temperature in the range 30 - 35 °C and are tested for viable counts of said organisms after 24 h.

25

38. A sterile, total-parenteral-nutrition composition for parenteral administration which comprises an oil-in-water emulsion in which a lipid is emulsified with water and which further comprises an
30 amount of sulfite sufficient to prevent a no more than 10-fold increase in the growth of each of *Staphylococcus aureus* (ATCC 6538), *Escherichia coli* (ATCC 8739),

Pseudomonas aeruginosa (ATCC 9027), and *Candida albicans* (ATCC 10231) for at least 24 h as measured by a test wherein a washed suspension of each organism is added to a separate aliquot of said composition at approximately
5 50 colony-forming units per mL and incubated at a temperature in the range 30 - 35 °C and are tested for viable counts of said organisms after 24 h.

39. A sterile, pharmaceutical composition for
10 parenteral administration which comprises an oil-in-water emulsion in which a lipophilic pharmaceutical or therapeutic agent is dissolved in a water-immiscible solvent, is emulsified with water, and is stabilized by means of a surfactant, and which further comprises an
15 amount of sulfite sufficient to prevent a no more than 10-fold increase in the growth of each of *Staphylococcus aureus* (ATCC 6538), *Escherichia coli* (ATCC 8739), *Pseudomonas aeruginosa* (ATCC 9027), and *Candida albicans* (ATCC 10231) for at least 24 h as measured by a test
20 wherein a washed suspension of each organism is added to a separate aliquot of said composition at approximately 50 colony-forming units per mL and incubated at a temperature in the range 30 - 35 °C and are tested for viable counts of said organisms after 24 h.

40. A sterile, pharmaceutical composition for parenteral administration which comprises an oil-in-water emulsion in which a lipophilic pharmaceutical or therapeutic agent is emulsified with water and is
5 stabilized by means of a surfactant, and which further comprises an amount of sulfite sufficient to prevent a no more than 10-fold increase in the growth of each of *Staphylococcus aureus* (ATCC 6538), *Escherichia coli* (ATCC 8739), *Pseudomonas aeruginosa* (ATCC 9027), and
10 *Candida albicans* (ATCC 10231) for at least 24 h as measured by a test wherein a washed suspension of each organism is added to a separate aliquot of said composition at approximately 50 colony-forming units per mL and incubated at a temperature in the range 30 - 35 °C
15 and are tested for viable counts of said organisms after 24 h.

41. A method for inducing anesthesia comprising parenteral administration of a composition which
20 comprises an oil-in-water emulsion in which propofol is dissolved in a water-immiscible solvent, is emulsified with water, and is stabilized by means of a surfactant, and which further comprises an amount of sulfite sufficient to prevent a no more than 10-fold increase in
25 the growth of each of *Staphylococcus aureus* (ATCC 6538), *Escherichia coli* (ATCC 8739), *Pseudomonas aeruginosa* (ATCC 9027), and *Candida albicans* (ATCC 10231) for at least 24 h as measured by a test wherein a washed suspension of each organism is added to a separate
30 aliquot of said composition at approximately 50 colony-forming units per mL and incubated at a temperature in the range 30 - 35 °C and are tested for viable counts of

said organisms after 24 h.

42. The method for inducing anesthesia according to claim 41 wherein the method of administration is by intravenous injection.

43. The method for inducing anesthesia according to claim 42 wherein the injection is by a single injection.

10

44. The method for inducing anesthesia according to claim 42 wherein the injection is by multiple injections.

15

45. The method for inducing anesthesia according to claim 41 wherein the method of administration is by continuous infusion.

46. A method of maintaining anesthesia comprising parenteral administration of a composition which comprises an oil-in-water emulsion in which propofol is dissolved in a water-immiscible solvent, is emulsified with water, and is stabilized by means of a surfactant, and which further comprises an amount of sulfite sufficient to prevent a no more than 10-fold increase in the growth of each of *Staphylococcus aureus* (ATCC 6538), *Escherichia coli* (ATCC 8739), *Pseudomonas aeruginosa* (ATCC 9027), and *Candida albicans* (ATCC 10231) for at least 24 h as measured by a test wherein a washed suspension of each organism is added to a separate aliquot of said composition at approximately 50 colony-forming units per mL and incubated at a temperature in

30

the range 30 - 35 °C and are tested for viable counts of said organisms after 24 h.

47. The method of maintaining anesthesia according to claim 46 wherein the method of administration is by multiple bolus injections.

48. The method of maintaining anesthesia according to claim 46 wherein the method of administration is by continuous infusion.

49. A method of sedation comprising parenteral administration of a composition which comprises an oil-in-water emulsion in which propofol is dissolved in a water-immiscible solvent, is emulsified with water, and is stabilized by means of a surfactant, and which further comprises an amount of sulfite sufficient to prevent a no more than 10-fold increase in the growth of each of *Staphylococcus aureus* (ATCC 6538), *Escherichia coli* (ATCC 8739), *Pseudomonas aeruginosa* (ATCC 9027), and *Candida albicans* (ATCC 10231) for at least 24 h as measured by a test wherein a washed suspension of each organism is added to a separate aliquot of said composition at approximately 50 colony-forming units per mL and incubated at a temperature in the range 30 - 35 °C and are tested for viable counts of said organisms after 24 h.


50. The method of sedation according to claim 49 wherein the method of administration is by continuous infusion.

5 51. The process for the manufacture of compositions of claims 17, 35, or 36 comprising the steps of:

- a. Degassing the water for injection (WFI) by sparging with nitrogen;
- 10 b. Preparing an aqueous phase by adding glycerin and sodium hydroxide to about 80% WFI in a compounding tank while maintaining the temperature at approximately 40 °C;
- 15 c. Adding the egg-yolk phospholipid to said aqueous phase;
- d. Homogenizing said aqueous phase;
- e. Filtering said aqueous phase through a 5.0 µm filter;
- 20 f. Preparing an oil phase by dissolving propofol in soybean oil;
- g. Filtering said oil phase through a 0.45 µm filter;
- h. Combining and homogenizing said aqueous and oil phases;
- 25 i. Adding a solution of any of sodium metabisulfite, sodium bisulfite, sodium sulfite, potassium metabisulfite, or potassium sulfite, or any combination thereof, dissolved in WFI near the end of
- 30 the homogenization step;

- j. Adding sodium hydroxide or hydrochloric acid solution to adjust the pH;
 - k. Adjusting to volume with SWFI;
 - 5 l. Microfluidizing the crude emulsion to the target globule size and particle size distribution while maintaining the temperature at about 30 °C;
 - m. Filtering the propofol oil-in-water emulsion into a filling vessel;
 - 10 n. Filling and sealing containers under nitrogen; and
 - o. Autoclaving said containers.
- 15 52. The method of claim 51 wherein all of said steps are performed under an inert atmosphere.
53. The method of claim 52 wherein said inert atmosphere is a nitrogen atmosphere.
- 20

1/ 1

COMPOUND PROCESS FLOW FOR
PROPOFOL INJECTABLE EMULSION (WITH SODIUM METABISULFITE)

INTERNATIONAL SEARCH REPORT

Intern. Appl. No.
PCT/US 99/03036

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/107 A61K47/02 A61K31/05

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GB 2 298 789 A (ZENECA) 18 September 1996 (1996-09-18) cited in the application the whole document	1-53
A	WO 97 10814 A (VESIFACT) 27 March 1997 (1997-03-27) the whole document	1-53
A	US 5 637 625 A (D.H.HAYNES) 10 June 1997 (1997-06-10) the whole document	1-53

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

20 July 1999

Date of mailing of the international search report

26/07/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 03036

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 41-50
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 41-50
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. Application No

PCT/US 99/03036

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2298789 A	18-09-1996	BR 9510452 A	19-05-1998
		DE 19509828 A	19-09-1996
		FR 2731617 A	20-09-1996
		WO 9629064 A	26-09-1996
		AU 1898895 A	08-10-1996
		CZ 9702904 A	17-12-1996
		DK 106697 A	17-09-1997
		EP 0814787 A	07-01-1998
		FI 973702 A	16-09-1996
		IT MI950529 A	22-09-1995
		LU 90136 A	27-11-1997
		NO 974278 A	16-09-1997
		PL 322278 A	19-01-1998
		SE 9703274 A	10-09-1997
		SK 124797 A	14-01-1998
		US 5908869 A	01-06-1999
		US 5714520 A	03-02-1998
		US 5731355 A	24-03-1998
		US 5731356 A	24-03-1998
		JP 11500737 T	19-01-1999
WO 9710814 A	27-03-1997	AU 6708096 A	09-04-1997
US 5637625 A	10-06-1997	AT 182074 T	15-07-1999
		AU 2329297 A	10-10-1997
		CA 2249375 A	25-09-1997
		EP 0796616 A	24-09-1997
		FI 982009 A	17-09-1998
		NO 984370 A	18-09-1998
		WO 9734588 A	25-09-1997